Clinically considerable immune-mediated hematologic adverse reactions (such as hemolytic anemia, aplastic anemia, immune thrombocytopenic purpura) transpired at an incidence of less than 1% in patients who been given this drug or had been noted with the usage of other PD-1/PD-L1 blocking antibodies.These can come about because Keytruda may bring ab